-
Hemlibra approved for all those with severe hemophilia A in Quebec – Access starts April 1
by David Page, CHS National Director of Health Policy March 1, 2022, Montréal – The Canadian Hemophilia Society (CHS) was informed yesterday by Héma-Québec that access...
-
Update on access to coagulation products for hemophilia A and B
by David Page, CHS National Director of Health Policy Access to a wide range of coagulation products is expanding in the provinces and territories served by...
-
Has the bleeding disorder world fundamentally changed?
by David Page, CHS National Director of Health Policy Given recent advances in therapies for inherited bleeding disorders, especially hemophilia A and B, I have...
-
Emicizumab rollout well underway
Montreal, December 16, 2021 – The rollout of emicizumab (Hemlibra) in the provinces and territories served by Canadian Blood Services (CBS) is well underway. Emicizumab...
-
Novel treatments in bleeding disorders: The EHC November Review
CLICK HERE to access the November 2021 review of novel treatments in haemophilia and other bleeding disorders by the European Haemophilia Consortium.